Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of LXR623, liver X receptor agonist, on colon cancer cells

ABSTRACT: Effect of LXR623, liver X receptor agonist, on colon cancer cells

PROVIDER: PRJNA432956 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Effect of LXR623, liver X receptor agonist, on glioma cells

Project description:Effect of LXR623, liver X receptor agonist, on glioma cells

| PRJNA432955 | ENA

Effect of LXR623, liver X receptor agonist, on colon cancer cells

Project description:We performed micro array analysis in order to evaluate the effect of LXR623 on gene expression in colon cancer cells (HCT116).

2019-02-05 | GSE110151 | GEO

Project description:DY131 is a pharmacological agonist of the orphan receptor estrogen-related receptor (ERR) γ which plays a crucial role in regulating energy generation, oxidative metabolism, cell apoptosis, inflammatory responses, etc. However, its role in acute liver injury is unknown. In the study, we evaluated the effect of DY131 on lipopolysaccharide (LPS)-induced liver injury. Transcriptomics analysis revealed that the dysregulated pathways associated with inflammation and metabolism were significantly reversed by DY131 in LPS-treated mice, providing more evidence in favor of the protective effect of DY131 against LPS-induced liver injury.

2020-11-06 | GSE160880 | GEO

A specific Peroxisome Proliferator-Activated Receptor (PPAR)-delta agonist is hepatoprotective and attenuates liver fibrogenesis

Project description:PPARδ is emerging as a key metabolic regulator with pleiotropic actions on various tissues including fat, skeletal muscle and liver. The aim of our study was to assess the effect of either the well-validated PPARδ agonist GW501516, or a novel PPARδ agonist KD3010 in mouse models of liver fibrosis. KD3010, but not GW501516, treated mice had markedly less liver injury induced by carbon tetrachloride (CCl4) injections. Deposition of extracellular matrix proteins was lower in the KD3010 group as compared to the vehicle or GW501516 treated group. Interestingly, profibrogenic CTGF was significantly induced by GW501516, but not KD3010, following CCl4 treatment. The hepatoprotective and antifibrotic effect of KD3010 was confirmed in a model of cholestasis-induced liver injury and fibrosis using bile duct ligation for three weeks. Hepatocytes were identified as targets for PPARδ agonist, and primary hepatocytes treated with KD3010 showed decreased serum starvation or CCl4-induced cell death, while GW501516 treated hepatocytes were not protected. KD3010 treatment of hepatocytes decreased reactive oxygen species (ROS) production after CCl4 exposure. In conclusion, our data demonstrate that a novel PPARδ agonist has hepatoprotective and antifibrotic effects in animal models of liver fibrosis. Given the oral availability and the favorable pharmacologic profile of KD3010, ligand activation of PPARδ represents an attractive and promising target for patients with chronic liver diseases. Total RNA was extracted from primary mouse hepatocytes treated with DMSO or PPARd agonists (KD3010, GW1516)

2012-04-18 | E-GEOD-32121 | biostudies-arrayexpress

Effect of PGE receptor EP3 subtype agonist on mouse asthma model

Project description:We examined the effect of PGE receptor EP3 subtype on mouse OVA-induced asthma model. We treat EP3 agonist 3h after OVA challenge. After 24 h of 3rd OVA challenge, whole lung was isolated and the gene expression change was determined. Keywords: other

2005-02-18 | GSE2276 | GEO

Expression data from fatty acid and bile acid receptor agonist treated liver sinusoidal endothelial cells

Project description:Liver sinusoidal endothelial cells (LSEC) are unique endothelial cell typelining the sinusoids of the liver and we have shown that these cells respond in a unique matter when exposed to saturated and unsaturated free fatty acids (FFA) and bile acids. We used microarray to analyze the transcriptional differences between the LSEC exposed to free fatty acids and bile acid receptor agonists to further shed light on their role in non-alcoholic fatty liver disease. The Murine Liver Sinusoidal Endothelial Cell Line (TSEC) was treated with palmitic and oleic acid or the bile acid receptor agonist INT-767 for 8 hours. Total RNA was then harvested to determine transcriptional differences.

2015-05-07 | E-GEOD-67651 | biostudies-arrayexpress

A specific Peroxisome Proliferator-Activated Receptor (PPAR)-delta agonist is hepatoprotective and attenuates liver fibrogenesis

2012-04-19 | GSE32121 | GEO

Project description:Estrogen-related receptor γ agonist DY131 ameliorates lipopolysaccharide-induced acute liver injury

| PRJNA674766 | ENA

The effect of GLP-1 receptor agonist Lixisenatide on experimental diabetic retinopathy

Project description:The effect of GLP-1 receptor agonist Lixisenatide on experimental diabetic retinopathy

| PRJNA990646 | ENA

The effect pregnane receptor X (PXR) agonist PCN on hepatic gene expression in mouse liver with and without glucose

Project description:The effect pregnane receptor X (PXR) agonist PCN on hepatic gene expression in mouse liver with and without glucose

| PRJNA517179 | ENA